<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468920</url>
  </required_header>
  <id_info>
    <org_study_id>17-114</org_study_id>
    <nct_id>NCT03468920</nct_id>
  </id_info>
  <brief_title>Preoperative IV Versus Oral Acetaminophen</brief_title>
  <official_title>Comparison of Outcomes When Patients Receive Preoperative IV Acetaminophen Versus Preoperative Oral Acetaminophen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study proposes to examine whether there is a significant difference in patient
      outcomes related to the administration route of preoperative Acetaminophen. Specifically, the
      study will compare outcomes of surgical patients who receive IV Acetaminophen with surgical
      patients who receive oral Acetaminophen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use a randomized, double-blind, controlled design with two arms:

      Arm 1: Scheduled IV Acetaminophen and PO placebo provided preoperatively Arm 2: Scheduled PO
      Acetaminophen and IV placebo provided preoperatively

      120 patients will be randomized 1:1 into Arm 1 or Arm 2. All other care, except route of
      preoperative Acetaminophen, will follow standard care procedures. The following outcome
      measures will be collected: postoperative pain, postoperative opioid medication
      administration, postoperative nausea and vomiting, occurrence of respiratory depression
      postoperatively, occurrence of administration of reversal agent postoperatively, length of
      stay in recovery room, patient satisfaction with pain control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">April 12, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will use a randomized, double-blind, placebo controlled design with two arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only pharmacy staff will have randomization scheme and be aware of whether patient received oral Acetaminophen with IV placebo OR if the patient received IV Acetaminophen with oral placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Reported Pain</measure>
    <time_frame>through study visit, less than 24 hours</time_frame>
    <description>Pain measured from 0 (no pain) to 10 (worst pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Opioid Administration in PACU</measure>
    <time_frame>through study visit, less than 24 hours</time_frame>
    <description>Number of Participants who Received Opioid Administration in PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Postoperative Nausea and Vomiting</measure>
    <time_frame>through study visit, less than 24 hours</time_frame>
    <description>Did patient experience negative effects of pain medication (postoperative nausea and vomiting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>through study visit, less than 24 hours</time_frame>
    <description>Minutes from entering PACU to end of Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>up to 2 days after surgery</time_frame>
    <description>Patient reported satisfaction with pain control on a scale of 1 (extremely unsatisfied) to 10 (extremely satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Arm 1: IV Acetaminophen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: PO Acetaminophen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively</description>
    <arm_group_label>Arm 1: IV Acetaminophen group</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PO Acetaminophen</intervention_name>
    <description>Acetaminophen PO 1000mg once pre-operatively</description>
    <arm_group_label>Arm 2: PO Acetaminophen group</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PO Placebo</intervention_name>
    <description>PO placebo capsule compounded to match PO Acetaminophen capsule</description>
    <arm_group_label>Arm 1: IV Acetaminophen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Solution Placebo</intervention_name>
    <description>This will serve as the placebo for the IV Acetaminophen intervention</description>
    <arm_group_label>Arm 2: PO Acetaminophen group</arm_group_label>
    <other_name>IV Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or older

          -  Admitted to Bethesda Butler Main Perioperative Services for an outpatient surgical
             procedure performed under general anesthesia

        Exclusion Criteria:

          -  Allergy to Acetaminophen

          -  Lactose intolerance or lactose allergy (placebo capsules contain lactose)

          -  Hepatic disease

          -  Having taken a product containing acetaminophen within 6 hours of scheduled surgery
             time

          -  Pregnant

          -  Weight less than 50kg

          -  Opioid addiction - admits to current opioid addiction and/or substance abuse disorder,
             and/or currently in treatment for opioid addiction or substance abuse

          -  Emergent or on-call procedures

          -  Inpatient surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>TriHealth, Bethesda Butler Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <results_first_submitted>April 12, 2019</results_first_submitted>
  <results_first_submitted_qc>April 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TriHealth Inc.</investigator_affiliation>
    <investigator_full_name>Rachel Baker</investigator_full_name>
    <investigator_title>Nurse Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03468920/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: IV Acetaminophen Group</title>
          <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: PO Acetaminophen Group</title>
          <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: IV Acetaminophen Group</title>
          <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: PO Acetaminophen Group</title>
          <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="60"/>
                    <count group_id="B3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.37" spread="15.82"/>
                    <measurement group_id="B2" value="46.28" spread="16.84"/>
                    <measurement group_id="B3" value="45.83" spread="16.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="60"/>
                    <count group_id="B3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="60"/>
                    <count group_id="B3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Reported Pain</title>
        <description>Pain measured from 0 (no pain) to 10 (worst pain)</description>
        <time_frame>through study visit, less than 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: IV Acetaminophen Group</title>
            <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PO Acetaminophen Group</title>
            <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Pain</title>
          <description>Pain measured from 0 (no pain) to 10 (worst pain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="3.092"/>
                    <measurement group_id="O2" value="4.37" spread="3.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Opioid Administration in PACU</title>
        <description>Number of Participants who Received Opioid Administration in PACU</description>
        <time_frame>through study visit, less than 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: IV Acetaminophen Group</title>
            <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PO Acetaminophen Group</title>
            <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Opioid Administration in PACU</title>
          <description>Number of Participants who Received Opioid Administration in PACU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Postoperative Nausea and Vomiting</title>
        <description>Did patient experience negative effects of pain medication (postoperative nausea and vomiting)</description>
        <time_frame>through study visit, less than 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: IV Acetaminophen Group</title>
            <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PO Acetaminophen Group</title>
            <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Postoperative Nausea and Vomiting</title>
          <description>Did patient experience negative effects of pain medication (postoperative nausea and vomiting)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <description>Minutes from entering PACU to end of Phase II</description>
        <time_frame>through study visit, less than 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: IV Acetaminophen Group</title>
            <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PO Acetaminophen Group</title>
            <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Minutes from entering PACU to end of Phase II</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.25" spread="26.651"/>
                    <measurement group_id="O2" value="92.88" spread="29.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient reported satisfaction with pain control on a scale of 1 (extremely unsatisfied) to 10 (extremely satisfied)</description>
        <time_frame>up to 2 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: IV Acetaminophen Group</title>
            <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PO Acetaminophen Group</title>
            <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient reported satisfaction with pain control on a scale of 1 (extremely unsatisfied) to 10 (extremely satisfied)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.45" spread="0.950"/>
                    <measurement group_id="O2" value="9.77" spread="0.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: IV Acetaminophen Group</title>
          <description>Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
IV Acetaminophen: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
PO Placebo: PO placebo capsule compounded to match PO Acetaminophen capsule</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: PO Acetaminophen Group</title>
          <description>Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
PO Acetaminophen: Acetaminophen PO 1000mg once pre-operatively
IV Solution Placebo: This will serve as the placebo for the IV Acetaminophen intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nurse Researcher</name_or_title>
      <organization>TriHealth</organization>
      <phone>513-569-6191</phone>
      <email>Rachel_Baker2@trihealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

